Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2011

View Archived Issues

TAK-075 is a new, stable, orally active bone anabolic agent for osteoporosis

Acetone level in exhaled breath as a new biomarker of heart failure

Merck & Co. describes new inhibitors of MAP/microtubule affinity-regulating kinase 3

Clinical phase I and II data presented on TMC-435 for hepatitis C

EMD-1204831 shows antitumor activity in preclinical studies

Cellmid reports preclinical data on midkine in acute myocardial infarction

Carbamate-based NCEH inhibitor AX-13057 shows promising potency

AstraZeneca presents potent new MAPK 14 inhibitors

ASP-3026 shows antitumor activity in murine model of NSCLC

MorphoSys and ContraFect join to develop therapeutic antibodies for infectious diseases

Preclinical data suggest benefit of allopurinol in diabetes-related nephropathy

REP-9AC shows promise as a therapy for hepatitis B

Enanta prepares new HCV NS5A inhibitors

RegeneRx refocuses clinical development program

Apricus Biosciences seeks FDA orphan drug status for RayVa in systemic sclerosis

Access Pharmaceuticals enters agreement for RNAi therapeutic delivery technologies

Amunix and Biogen Idec enter research agreement for recombinant blood factors

Regulus and UCSD to seek new microRNA therapeutics for angiogenic diseases

U.S. Department of Defense awards grant to study ganaxolone in fragile X syndrome

InSite Vision files response regarding SPA for phase III blepharitis study

FDA receives reports of hepatosplenic T-cell lymphoma in patients on TNF inhibitors

Galapagos discontinues phase II trial of GLPG-0259 in rheumatoid arthritis

Axcan to acquire Mpex Pharmaceuticals

Takeda lauches Edarbi for the treatment of hypertension in the U.S.

GSK submits MAA in Europe for Tyverb with paclitaxel in metastatic breast cancer

Proteon begins enrollment in phase II study of PRT-201 in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...